Abstract:Objective To compare the efficacy and safety of insulin glulisine and insulin lispro combined with insulin glargine in patients with diabetes mellitus. Methods This was a multi-centre randomly controlled study.Thirty four patients with type 1 and 450 patients with type 2 diabetes mellitus with a HbAlc level of 6.5％ to 11.0％ and more than 3 months of continuous insulin treatment immediately prior to study entry were enrolled from February 2007 to June 2008.After 4-week run-in period with insulin lispro (three times a day,0-15 min before the meals) combined with insulin glargine treatment (once daily before breakfast),all the subjects were randomized (3:1 ) to receive a 12-week treatment with insulin glulisine or insulin lispro in combination with insulin glargine.The data collected at the visit after the 4-weeks run-in period was defined as the baseline data.The change in HbAlc,blood glucose,treatment satisfaction and incidence of hypoglycemia after the treatment was recorded and compared.The data of the two groups were compared by using an ANOVA model.Results After 12-week of treatment,HbA1 c reduced from 8.7％ ±1.2％ to7.9％ ±1.0％ in insulin glulisine group,and from 8.8％ ±1.2％ to 7.9％ ±1.0％ in insulin lispro group (compared with baseline,t =- 12.55 and - 8.88,both P ＜0.05).Fasting plasma glucose (FPG) decreased significantly compared with baseline in both groups: for insulin glulisine group,from (8.6 ±2.8) mmoL/L to (7.7 ±2.5) mmoL/L,and for insulin lispro group,from (8.6 ±2.5) mmol/L to (7.8 ± 2.2) mmol/L ( compared with baseline,t =- 6.55 and - 2.98,both P ＜ 0.05 ).The 2 h postprandial glucose (2 h PPG) decreased significantly in insulin glulisine group (from ( 10.6 ± 3.8)mmol/L to ( 10.2 ±3.7) mmol/L,t =- 2.07,P =0.04),but it was no difference in insulin lispro group ( from ( 10.9 ± 4.0) mmol/L to ( 10.4 ± 3.5 ) mmol/L,t =- 1.37,P ＞ 0.05 ).The incidence of all categories of symptomatic hypoglycemia was comparable between the two groups (33.9％ vs 34.7％ ) during treatment period.An increase of satisfaction scores after treatment was found both in the insulin glulisine group (from 29 ±5 to 31 ±5,t =6.81 P ＜0.05) and insulin lispro group (from 29 ±5 to 31 ±4,t =4.21,P ＜0.05).Conclusions It showed that when used in combination with insulin glargine,insulin glulisine is clinical equivalent to insulin lispro in decreasing HbA1c and plasma glucose in Chinese patients with diabetes mellitus.Both regimens are well tolerated and safe.

Comparison of Controlled-Release Formulation of Glipizide and Immediate-Release Glipizide in Clinical Efficacy and Safety

Effects and patient compliance of sustained-release versus immediate-release glipizides in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.

Efficacy and Safety in Type 2 Diabetes Treated by Controlled-release-gliclazide in Comparison with Gliclazide

Comparative Efficacy and Safety of Glucose-Lowering Drugs as Monotherapy for Type 2 Diabetes: A Systematic Review and Indirect Treatment Comparison

Clinical Study of Controlled-Release formula of Glipizide in the Treatment of Coronary Artery Disease Complicated with Type 2 Diabetes Mellitus

A Double-Blind Randomized Multiple Center Clinical Trial on Observing the Effect of Fixed-Dose Glipizide/metformin on Type 2 Diabetes

Comparison of Efficacy and Quality of Life in Type 2 Diabetics Treated with Controlled-Release-gliclazide and Ordinary Gliclazide Tablets

The Effects of Glipizide-GITS and Gliclazide on Insulin Resistance and Islet Β-Cell Function in Patients with Type 2 Diabetes

Comparision of glimepiride and glibenclamide on cardiovascular risk factors in patients with newly diagnosed type 2 diabetes mellitus

Clinical Effects of Gliclazide Sustained-Release Tablets on Type 2 Diabetes Mellitus

Choice of Glucose-Lowering Drugs As Initial Monotherapy for Type 2 Diabetes Patients with Contraindications or Intolerance to Metformin: A Systematic Review and Meta-Analysis

Effect of Repaglinide and Gliclazide on Glycaemic Control, Early-Phase Insulin Secretion and Lipid Profiles In.

Efficacy and Safety of Additional Basal Insulin or Oral Antidiabetic Drug in Type 2 Diabetes Poorly Controlled with One Oral Antidiabetic Drug

Multi-center Study of Safety and Efficacy Evalution of Glimepiride in Type 2 Diabetic Patients

Efficacy and Safety Between Two Dosages of Gliclazide Modified Release Tablets (30 Mg and 60 Mg Once Daily) in the Treatment of Patients with Newly Diagnosed Type 2 Diabetes

Comparative efficacy and safety of glucagon-like peptide 1 receptor agonists for the treatment of type 2 diabetes: A network meta-analysis

Comparison of the Efficacy and Safety of Insulin Glulisine and Insulin Lispro Combined with Insulin Glargine in Patients with Diabetes

Comparison of the effect of different short-term intensive anti-diabetic therapies on newly diagnosed type 2 diabetic patients.

The efficacy and safety of GLP-1 analogue and glargine on type 2 diabetic patients:A meta-analysis

A Multicenter,randomized,open-Labelled,nph Parallel Controlled Study to Evaluate the Efficacy and Safety of Once Daily Injection of Glargine Combined with Glipizide GITS in the Treatment of Poor-Controled Type Ⅱ Diabetes Mellitus

Comparison of Efficacy and Safety of Liraglutide and Glimepiride in Combination with Metformin in Type 2 Diabetes